Reply to Nannini and to Lipworth .
作者信息
Peters Michael C, Fahy John V, Denlinger Loren C
机构信息
University of California San Francisco, San Francisco, California, and.
University of Wisconsin, Madison, Wisconsin.
出版信息
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1325-1326. doi: 10.1164/rccm.202006-2531LE.
Abstract
摘要
相似文献
1
Reply to Nannini and to Lipworth .致南尼尼和利普沃思的回复。
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1325-1326. doi: 10.1164/rccm.202006-2531LE.
2
Reply to Lipworth : Sex Hormones and Asthma: Don't Forget Progesterone.对利普沃思的回应：性激素与哮喘：别忘了孕酮。
Am J Respir Crit Care Med. 2020 Feb 1;201(3):392-393. doi: 10.1164/rccm.201910-1941LE.
3
Differences in asthma study models and the effectiveness of β2 -adrenoceptor ligands: response to Lipworth et al.哮喘研究模型的差异与β2-肾上腺素能受体配体的有效性：对利普沃思等人的回应
Br J Pharmacol. 2016 Jan;173(1):250-1. doi: 10.1111/bph.13334.
4
Reply to Lipworth and Kuo: Resistance Heterogeneity and Small Airway Asthma Phenotype.对利普沃思和郭的回应：耐药异质性与小气道哮喘表型。
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1442. doi: 10.1164/rccm.201906-1274LE.
5
Reply to Lipworth : Inhaled Corticosteroids and COVID-19.对利普沃思的回复：吸入性糖皮质激素与2019冠状病毒病
Am J Respir Crit Care Med. 2020 Sep 15;202(6):900-902. doi: 10.1164/rccm.202006-2129LE.
6
Reply to Moitra et al.: Individual Chronotype May Confound Asthma Symptoms and Therapy.
Am J Respir Crit Care Med. 2019 Feb 1;199(3):392-394. doi: 10.1164/rccm.201809-1712LE.
7
Reply to Nannini and to a previous letter by Hurley.
Clin Infect Dis. 2006 Apr 15;42(8):1204-5. doi: 10.1086/502654.
8
Reply to Nannini and Arias.
Clin Infect Dis. 2013 Jun;56(11):1679-80. doi: 10.1093/cid/cit091. Epub 2013 Feb 15.
9
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):211-212. doi: 10.1164/rccm.202305-0792LE.
10
Reply to Lipworth and Chan.对利普沃思和陈的回复。
Am J Respir Crit Care Med. 2023 Jul 15;208(2):212-213. doi: 10.1164/rccm.202305-0843LE.
本文引用的文献
1
Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency.哮喘加重倾向的证据和加重频率的预测生物标志物。
Am J Respir Crit Care Med. 2020 Oct 1;202(7):973-982. doi: 10.1164/rccm.201909-1813OC.
2
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.肥胖在肿瘤进展和 PD-1 检查点阻断过程中对 T 细胞功能的矛盾影响。
Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.
3
A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma.一种用于确定 T2 高和 T2 低哮喘气道免疫功能障碍的转录组学方法。
Am J Respir Crit Care Med. 2019 Feb 15;199(4):465-477. doi: 10.1164/rccm.201807-1291OC.
4
Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.严重哮喘研究计划（SARP III）队列的基线特征：年龄差异。
J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):545-554.e4. doi: 10.1016/j.jaip.2017.05.032. Epub 2017 Aug 31.
5
A system model of the effects of exercise on plasma Interleukin-6 dynamics in healthy individuals: Role of skeletal muscle and adipose tissue.运动对健康个体血浆白细胞介素-6动态影响的系统模型：骨骼肌和脂肪组织的作用。
PLoS One. 2017 Jul 12;12(7):e0181224. doi: 10.1371/journal.pone.0181224. eCollection 2017.
6
Metabolic consequences of obesity as an "outside in" mechanism of disease severity in asthma.肥胖的代谢后果作为哮喘疾病严重程度的一种“由外而内”机制。
Eur Respir J. 2016 Aug;48(2):291-3. doi: 10.1183/13993003.01132-2016.
7
Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.血浆白细胞介素-6 浓度、代谢功能障碍与哮喘严重程度：两个队列的横断面分析。
Lancet Respir Med. 2016 Jul;4(7):574-584. doi: 10.1016/S2213-2600(16)30048-0. Epub 2016 Jun 6.
8
Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine.肥胖诱导的慢性炎症与流感疫苗效力降低有关。
Hum Vaccin Immunother. 2014;10(5):1181-6. doi: 10.4161/hv.28332. Epub 2014 Mar 10.
9
Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model.通过微创模型证明人类在运动过程中白细胞介素-6 的来源和动力学。
Eur J Appl Physiol. 2011 Jul;111(7):1351-9. doi: 10.1007/s00421-010-1755-5. Epub 2010 Dec 10.
Zotero 插件